| Combination of | |
|---|---|
| Naproxen | NSAID |
| Esomeprazole | Proton pump inhibitor |
| Clinical data | |
| Trade names | Vimovo |
| AHFS/Drugs.com | Professional Drug Facts |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Naproxen/esomeprazole, sold under the brand name Vimovo, is a pain reliever medication in the form of a tablet for oral consumption, containing naproxen, a nonsteroidal anti-inflammatory drug (NSAID), and a delayed release formulation of esomeprazole, a stomach acid–reducing proton-pump inhibitor (PPI).[2][3] It is produced by AstraZeneca.[4] Vimovo is US Food and Drug Administration approved for use against osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.[2] It is intended to decrease the risk of gastric ulcers from treatment with NSAIDs.[2]
It is available as a generic medication.[5] In 2020, it was the 390th most commonly prescribed medication in the United States, with more than 300 thousand prescriptions.[6][7]
Adverse effects
Society and culture
Economics
Vimovo was acquired by the Ireland-based company, Horizon Pharma on November 19, 2013. AstraZeneca retained "ex-U.S. rights to Vimovo".[3]
In a June 2017 article in The Atlantic, journalist Marshall Allen wrote that, the cost of Aleve and Nexium, the two common medications" that became the specialty drug Vimovo, was $40 a month. Horizon Pharma bills insurance companies $3,252 a month for Vimovo.[8] According to The Atlantic, "since 2014, Horizon Pharma's net sales have been more than $455 million".[8]
References
- ^ "Esomeprazole / naproxen (Vimovo) Use During Pregnancy". Drugs.com. 11 September 2019. Retrieved 17 August 2020.
- ^ a b c d "Vimovo- naproxen and esomeprazole magnesium tablet, delayed release". DailyMed. Retrieved 5 May 2021.
- ^ a b "Horizon Pharma Announces Agreement to Acquire U.S. Rights to Vimovo and Provides 2014 Guidance". Horizon Pharma, Inc. (Press release). Deerfield, Illinois. November 19, 2013.
- ^ "Vimovo-Astrazeneca". felleskatalogen.no. Archived from the original on 2021-04-26. Retrieved 2017-06-20.
- ^ "Esomeprazole magnesium; Naproxen". Drugs@FDA: FDA-Approved Drugs. U.S. Food and Drug Administration.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
- ^ "Esomeprazole; Naproxen - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
- ^ a b Allen M (June 20, 2017). "How Two Common Medications Became One $455 Million Specialty Pill". The Atlantic. Retrieved June 20, 2017.
After I was prescribed a brand-name drug I didn't need and given a coupon to cover the out-of-pocket costs, I discovered yet another reason why Americans pay too much for health care.
External links
- "Esomeprazole magnesium mixture with naproxen". Drug Information Portal. U.S. National Library of Medicine.
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams |
|
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 20 December 2023, at 19:23